91
Participants
Start Date
November 30, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
bevacizumab [Avastin]
10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
fotemustine
75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
Genoa
Milan
Milan
Treviso
Padua
Bologna
San Giovanni Rotondo
Napoli
Rome
Terni
Hoffmann-La Roche
INDUSTRY